Preoperative systemic inflammatory markers are prognostic indicators in recurrent adrenocortical carcinoma.
adrenocortical cancer
lymphocyte
monocyte
recurrence
Journal
Journal of surgical oncology
ISSN: 1096-9098
Titre abrégé: J Surg Oncol
Pays: United States
ID NLM: 0222643
Informations de publication
Date de publication:
Dec 2019
Dec 2019
Historique:
received:
03
07
2019
accepted:
01
11
2019
pubmed:
17
11
2019
medline:
4
12
2019
entrez:
17
11
2019
Statut:
ppublish
Résumé
Recurrent adrenocortical carcinoma (ACC) has a poor prognosis with minimal clinical and biochemical factors to guide management. The aim of this study was to evaluate the prognostic significance of systemic inflammatory response in patients with recurrent ACC. Patients who underwent resection for recurrent ACC were retrospectively analyzed. Preoperative neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, lymphocyte-to-monocyte ratio (LMR), and mean platelet volume were calculated. Twenty-five patients (age at operation 52.2 ± 9.5 years) were identified. We observed a statistically significant shorter disease-specific survival (DSS) in patients with LMR less than 4 (41 ± 7.4 months vs 71 ± 12.3, P = .023) and male sex (26.6 ± 4.2 months vs 57.6 ± 9.5 months, P = .079), while time-to-recurrence (TTR) less than 12 months (40 ± 7.7 months vs 70.3 ± 13.1 months, P = .059) had a trend on univariate analysis for worse DSS. On multivariable analysis, LMR < 4 (hazard ratio [HR] 4.18; 95% confidence interval [CI]: 1.18-14.76; P = .027) and TTR less than 12 months (HR 2.77 95% CI: 1-7.62; P = .049) were found to be significantly associated with worse DSS. Preoperative LMR greater than 4 and TTR greater than 12 months are associated with longer DSS. Patients with LMR greater than 4 and TTR greater than 12 months may benefit from a more aggressive therapeutic approach and may require less frequent surveillance.
Sections du résumé
BACKGROUND
BACKGROUND
Recurrent adrenocortical carcinoma (ACC) has a poor prognosis with minimal clinical and biochemical factors to guide management. The aim of this study was to evaluate the prognostic significance of systemic inflammatory response in patients with recurrent ACC.
METHODS
METHODS
Patients who underwent resection for recurrent ACC were retrospectively analyzed. Preoperative neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, lymphocyte-to-monocyte ratio (LMR), and mean platelet volume were calculated.
RESULTS
RESULTS
Twenty-five patients (age at operation 52.2 ± 9.5 years) were identified. We observed a statistically significant shorter disease-specific survival (DSS) in patients with LMR less than 4 (41 ± 7.4 months vs 71 ± 12.3, P = .023) and male sex (26.6 ± 4.2 months vs 57.6 ± 9.5 months, P = .079), while time-to-recurrence (TTR) less than 12 months (40 ± 7.7 months vs 70.3 ± 13.1 months, P = .059) had a trend on univariate analysis for worse DSS. On multivariable analysis, LMR < 4 (hazard ratio [HR] 4.18; 95% confidence interval [CI]: 1.18-14.76; P = .027) and TTR less than 12 months (HR 2.77 95% CI: 1-7.62; P = .049) were found to be significantly associated with worse DSS.
CONCLUSION
CONCLUSIONS
Preoperative LMR greater than 4 and TTR greater than 12 months are associated with longer DSS. Patients with LMR greater than 4 and TTR greater than 12 months may benefit from a more aggressive therapeutic approach and may require less frequent surveillance.
Identifiants
pubmed: 31733070
doi: 10.1002/jso.25760
pmc: PMC8192065
mid: NIHMS1704338
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1450-1455Subventions
Organisme : Intramural NIH HHS
ID : ZIA BC011286
Pays : United States
Organisme : NIH Clinical Center
Organisme : Center for Cancer Research, National Cancer Institute, National Institutes of Health
Informations de copyright
Published 2019. This article is a U.S. Government work and is in the public domain in the USA.
Références
J Clin Endocrinol Metab. 2013 Jan;98(1):181-91
pubmed: 23150691
Endocr J. 2008 Mar;55(1):49-55
pubmed: 18187873
Ann Surg Oncol. 2018 Jan;25(1):122-130
pubmed: 29134377
Cancer Invest. 2016 Sep 13;34(8):378-84
pubmed: 27558529
Cancer Immunol Immunother. 1990;30(6):342-50
pubmed: 2105845
Tumour Biol. 2014 Nov;35(11):11659-66
pubmed: 25139101
Ann Surg Oncol. 2014 Oct;21(11):3541-7
pubmed: 24833102
J Clin Oncol. 2011 Feb 20;29(6):610-8
pubmed: 21245428
J Clin Oncol. 2002 Feb 15;20(4):941-50
pubmed: 11844815
Immunobiology. 2013 Nov;218(11):1402-10
pubmed: 23891329
World J Gastroenterol. 2015 Oct 14;21(38):10898-906
pubmed: 26478681
Immunity. 2013 Oct 17;39(4):782-95
pubmed: 24138885
Cancer Cell. 2017 Sep 11;32(3):282-293
pubmed: 28898694
World J Surg. 2006 May;30(5):872-8
pubmed: 16680602
J Clin Endocrinol Metab. 2007 Jan;92(1):148-54
pubmed: 17062775
Nucleic Acids Res. 2015 Oct 30;43(19):9327-39
pubmed: 26446994
Cancer. 2008 Dec 1;113(11):3130-6
pubmed: 18973179
Cancer. 1950 Jan;3(1):32-5
pubmed: 15405679
Sci Rep. 2017 Dec 1;7(1):16717
pubmed: 29196718
Eur J Cancer. 2013 Jul;49(11):2579-86
pubmed: 23561851
Best Pract Res Clin Endocrinol Metab. 2009 Apr;23(2):273-89
pubmed: 19500769
J Surg Oncol. 2015 Aug;112(2):164-72
pubmed: 26234285
Ann Surg Oncol. 2015 Dec;22 Suppl 3:S714-20
pubmed: 26282908
Surgery. 2013 Dec;154(6):1292-9; discussion 1299
pubmed: 24238048
Nat Rev Cancer. 2004 Jan;4(1):71-8
pubmed: 14708027
Onco Targets Ther. 2016 Mar 01;9:1085-92
pubmed: 27042101
J Am Coll Surg. 2016 Dec;223(6):794-803
pubmed: 27618748